{"id":"W4281777449","doi":"10.1200/jco.2022.40.16_suppl.8014","title":"Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Neutropenia; Cytokine release syndrome; Adverse effect; Oncology; Common Terminology Criteria for Adverse Events; Transplantation; Minimal residual disease; Autologous stem-cell transplantation; Gastroenterology; Immunology; Immunotherapy; Chemotherapy; Chimeric antigen receptor; Bone marrow; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002717467,0.0006736774,0.001019359,0.0006716656,0.0001266071,0.0007964134,0.0005803652,0.000454878,0.001338162],"category_scores_gemma":[0.001468325,0.0001769875,0.0009383694,0.0007798084,0.0001816452,0.0005189315,0.0003270067,0.0009336313,0.0004159642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006696436,"about_ca_system_score_gemma":0.001040404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001337572,"about_ca_topic_score_gemma":0.002745638,"domain_scores_codex":[0.9996056,0.0001312168,0.00005345004,0.00004514237,0.0001131813,0.00005138177],"domain_scores_gemma":[0.9991115,0.0002656284,0.0002841416,0.00003343943,0.0001984707,0.0001068468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.009058147,0.0007518438,0.00834944,0.002570999,0.0008828599,0.0002149423,0.0001026355,0.001239335,0.01126804,0.0002642847,0.01535655,0.9499409],"study_design_scores_gemma":[0.01859636,0.05271191,0.2240697,0.003294677,0.01576905,0.005375267,0.0002619015,0.003721375,0.02296937,0.0008523465,0.6522131,0.0001649514],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1827515,0.7966616,0.003097486,0.004936348,0.0006443668,0.0005803625,0.003649913,0.0002669565,0.007411537],"genre_scores_gemma":[0.4155938,0.5415071,0.00959285,0.009575214,0.001645775,0.0007633048,0.01630693,0.0001177932,0.004897105],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002717467,"threshold_uncertainty_score":0.01437151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06754253009766986,"score_gpt":0.3958977306044321,"score_spread":0.3283552005067623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}